We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+18.5%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.29B
AUM Growth
-$221M
(-15%)
Cap. Flow
-$280M
Cap. Flow
% of AUM
-21.66%
Top 10 Holdings %
Top 10 Hldgs %
58.27%
Holding
48
New
1
Increased
5
Reduced
14
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
+$18.6M |
| 2 |
4D Molecular Therapeutics
FDMT
|
+$5.52M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$4.97M |
| 4 |
Vaxcyte
PCVX
|
+$4.74M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$3.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookfield
BN
|
+$59.8M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$54.7M |
| 3 |
Disc Medicine
IRON
|
+$44.4M |
| 4 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$30.7M |
| 5 |
ASML
ASML
|
+$19.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.31% |
| 2 | Technology | 28.76% |
| 3 | Industrials | 8.35% |
| 4 | Communication Services | 4.78% |
| 5 | Consumer Discretionary | 3.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ASML
ASML
$608B
| $143M | 11.07% |
197,760
-29,010
| -13% | -$19.7M |
|
2
Salesforce
CRM
$149B
| $112M | 8.66% |
530,500
-48,000
| -8% | -$9.8M |
|
3
LanzaTech
LNZA
$60.4M
| $108M | 8.35% |
158,148
| – | – |
|
4
Corcept Therapeutics
CORT
$10.1B
| $75.2M | 5.81% |
3,377,768
| – | – |
|
5
TSMC
TSM
$2.03T
| $71.7M | 5.54% |
710,780
| – | – |
|
6
Cable One
CABO
$249M
| $61.8M | 4.78% |
94,103
| – | – |
|
|
7
Disc Medicine
IRON
$2.85B
| $48.4M | 3.74% |
1,090,772
-1,250,000
| -53% | -$44.4M |
|
8
Edgewise Therapeutics
EWTX
$4.34B
| $47.1M | 3.64% |
6,071,703
| – | – |
|
9
Mirum Pharmaceuticals
MIRM
$6.84B
| $43.6M | 3.37% |
1,684,193
| – | – |
|
10
Apple
AAPL
$4.99T
| $43M | 3.32% |
221,460
-73,820
| -25% | -$12.9M |
|
|
11
Vaxcyte
PCVX
$7.88B
| $42.2M | 3.26% |
845,000
+100,000
| +13% | +$4.74M |
|
12
Alibaba
BABA
$276B
| $41.7M | 3.23% |
500,827
| – | – |
|
|
13
BioMarin Pharmaceuticals
BMRN
$12B
| $34.7M | 2.68% |
400,000
+32,620
| +9% | +$3.07M |
|
|
ACLX
14
DELISTED
Arcellx
ACLX
| $31.6M | 2.44% |
1,000,000
-225,000
| -18% | -$8.6M |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $30.8M | 2.38% |
159,986
+25,000
| +19% | +$4.97M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $28.4M | 2.19% |
448,804
| – | – |
|
17
Insmed
INSM
$22.6B
| $28.3M | 2.18% |
1,339,304
| – | – |
|
|
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
| $26.3M | 2.03% |
2,095,900
| – | – |
|
19
Alnylam Pharmaceuticals
ALNY
$38.5B
| $22.5M | 1.74% |
118,383
| – | – |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| $21.9M | 1.69% |
+2,000,000
| New | +$18.6M |
|
|
OKUR
21
OnKure Therapeutics
OKUR
$160M
| $21.8M | 1.69% |
333,038
-10,000
| -3% | -$806K |
|
|
22
Brookfield
BN
$104B
| $20.5M | 1.58% |
940,811
-2,822,434
| -75% | -$59.8M |
|
23
Pharvaris
PHVS
$2.35B
| $20.1M | 1.56% |
1,329,325
| – | – |
|
24
Crinetics Pharmaceuticals
CRNX
$8.88B
| $19.8M | 1.53% |
1,100,000
| – | – |
|
25
Rocket Pharmaceuticals
RCKT
$343M
| $18.3M | 1.41% |
920,000
| – | – |
|
Similar funds
HCA
GX
MP
FLII
CA
IC
WTA
CCA
Novo Holdings A/S's Q2 2023 Portfolio in Review
As of Q2 2023, Novo Holdings A/S held 48 positions worth $1.29B, down 15% from $1.52B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Novo Holdings A/S withdrew a net $280M in Q2 2023, closing 7 positions and reducing 14 holdings. Its most notable exit was CATALENT, INC., an estimated $54.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 57% a quarter earlier, followed by Technology and Industrials.
Against the trend, Novo Holdings A/S opened a new position in Cymabay Therapeutics worth $21.9M.
- Novo Holdings A/S's largest Q2 2023 buy was Cymabay Therapeutics: 2,000,000 shares worth $21.9M.
- Novo Holdings A/S added most to 4D Molecular Therapeutics in Q2 2023, an estimated $5.52M increase.
- Novo Holdings A/S's biggest Q2 2023 reduction was Brookfield, cutting an estimated $59.8M.
- Novo Holdings A/S fully exited CATALENT, INC. in Q2 2023, selling an estimated $54.7M.
- Novo Holdings A/S's ten largest holdings make up 58% of its $1.29B portfolio in Q2 2023.
- Novo Holdings A/S opened 1 new position and closed 7 in Q2 2023.
- Novo Holdings A/S's portfolio value fell 15% quarter-over-quarter to $1.29B.
Based on Novo Holdings A/S's 13F filing for Q2 2023, filed 14 Aug 2023.